Specific inhibitory MAbs to human P-450s used in this study
| Antihuman P-450* | MAb (ref.) | Ig Subtype | Enzyme-Linked Immunosorbent Assay | I B | % Inhibition | Substrate |
|---|---|---|---|---|---|---|
| 1A1 | 1-7-1 | IgG1 | + | − | >90 | 7-ECO, phenanthrene, chlorzoxazone |
| 1A2 | 26-7-5 | IgG1 | + | + | >90 | 7-EC, phenanthrene, IMI, chlorzoxazone |
| 2A6 | 151-45-4 | IgG1 | + | + | >90 | Coumarin, 4-nitrophenol, phenanthrene, 7-ECO |
| 2B6 | 49-10-20 | IgG2b | + | + | >90 | Testosterone, 7-EC, DZ, phenanthrene |
| 2C8/9/18/19 | 1-68-11 | IgM | + | − | >90 (2C9/18/19) >85 (2C8) | DZ, phenanthrene |
| 2D6 | 512-1-8 | IgG1 | + | + | >90 | Bufuralol, dextromethorphan, IMI |
| 2E1 | 1-73-18 | IgM | + | − | >90 | Phenanthrene,p-nitroanisole, toluene, chlorzoxazone, 4-methylanisole |
| 3A4/5 | 3-29-9 | IgM | + | − | >90 (3A4) >60–80 (3A5) | DZ, testosterone, Taxol, cyclosporin, phenanthrene |
All MAbs are specific to target P-450s as tested with human P450 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, 3A4, and 3A5.